ORUKA THERAPEUTICS INC (ORKA) Stock News

USA - Nasdaq - NASDAQ:ORKA - US6876041087 - Common Stock

30.79 USD

-0.66 (-2.08%)

Last: 12/9/2025, 8:22:10 PM

30.79 USD

0 (0%)

After Hours: 12/9/2025, 8:22:10 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ORKA Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Benzinga - Mentions: GILD CRWV CPSH VEEV

This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

a month ago - By: Benzinga - Mentions: CSCO DLTR AZO FDX ...

AutoZone To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Thursday

a month ago - By: Oruka Therapeutics, Inc.

Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

a month ago - By: Oruka Therapeutics, Inc.

Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

2 months ago - By: Stocktwits - Mentions: MLTX SLRN

News Image

MoonLake Stock Climbs After-Hours: Retail Traders Shrug Off Record Plunge, More Wall Street Downgrades

a month ago - By: Zacks Investment Research

Wall Street Analysts Predict a 63.59% Upside in Oruka Therapeutics, Inc. (ORKA): Here's What You Should Know

a month ago - By: Oruka Therapeutics, Inc.

Oruka Therapeutics to Present at Multiple November Investor Conferences

a month ago - By: Oruka Therapeutics, Inc.

Oruka Therapeutics to Present at Multiple November Investor Conferences

5 months ago - By: Oruka Therapeutics, Inc.

Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer

2 months ago - By: Investor's Business Daily - Mentions: MLTX

MoonLake Crashes 89% On Mixed Results For Skin Disease Treatment

3 months ago - By: Investor's Business Daily - Mentions: AAPL ABBV

Oruka Therapeutics, Up 20%, Is Trying To Take On AbbVie's Biggest Moneymaker

3 months ago - By: Oruka Therapeutics, Inc.

Oruka Therapeutics Announces $180 Million Private Placement

3 months ago - By: Oruka Therapeutics, Inc.

Oruka Therapeutics Announces $180 Million Private Placement

3 months ago - By: Oruka Therapeutics, Inc.

Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001

3 months ago - By: Oruka Therapeutics, Inc.

Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001

4 months ago - By: Oruka Therapeutics, Inc.

Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

4 months ago - By: Oruka Therapeutics, Inc.

Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

5 months ago - By: Oruka Therapeutics, Inc.

Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September

5 months ago - By: Oruka Therapeutics, Inc.

Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September

5 months ago - By: Oruka Therapeutics, Inc.

Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer

7 months ago - By: Yahoo Finance - Mentions: MLTX LUV

Fertility financing 101: How to afford IVF

7 months ago - By: Yahoo Finance - Mentions: MLTX PTON AAPL

H.C. Wainwright Maintains Buy Rating on MoonLake Immunotherapeutics (MLXT), Keeps PT

7 months ago - By: Yahoo Finance - Mentions: MLTX RXRX AAPL

H.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 Trial

7 months ago - By: Yahoo Finance - Mentions: HAS MGM V AAPL

Airwallex Raises $300M As It Expands In U.S. And Latin America, Now Valued At $6.2B With Clients Like Shein And Xero

7 months ago - By: Oruka Therapeutics, Inc.

Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference

7 months ago - By: Oruka Therapeutics, Inc.

Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference

7 months ago - By: Oruka Therapeutics, Inc.

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

7 months ago - By: Oruka Therapeutics, Inc.

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

7 months ago - By: Oruka Therapeutics, Inc.

Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update